跳至主要内容
临床试验/JPRN-UMIN000004592
JPRN-UMIN000004592已完成未知

Multicenter, placebo-controlled randomized trial for prevention of post ERCP pancreatitis with Risperidone - Tokyo P3R-2

Faculty of Medicine, University of Tokyo0 个研究点目标入组 500 人开始时间: 2010年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients with a history of ERCP. Patients with acute pancreatitis which need fasting therapy. Patients who have disseminated intravascular coagulation, sepsis, or acute circulatory failure. Patients with more severe disturbance of consciousness than Japan Coma Scale1-1. Patients who have severe heart disease, hepatic insufficiency, renal dysfunction, endocrine disease, or gastrointestinal tract disturbance. Pregnant or breast-feeding women. Women who have possibility of pregnancy or who are not willing to avoid pregnancy during the study. Patients who are treated with risperidone. Patients with severe hypersensitivity to risperidone Patients with mental illness or depression, who need drug therapy or can not comply with the protocol. Patients with Parkinson's disease or parkinsonism. Patients who have received banned drug within 2 weeks before ERCP Patients with chronic pancreatitis Patients who are judged inappropriate by chief (responsive) medical examiner

研究者

发起方
Faculty of Medicine, University of Tokyo

相似试验